View:
Download DOC
Download PDF
Download XLS
Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 14, 2019
ALEXION PHARMACEUTICALS, INC.
-----------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
000-27756
13-3648318
------------------
------------------
---------------
(State or other jurisdiction
of incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

121 Seaport Boulevard, Boston, Massachusetts 02210
---------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code:    (475) 230-2596
   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
¨

Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨





Item 5.07    Submission of Matters to a Vote of Security Holders.

Alexion Pharmaceuticals, Inc. held its Annual Meeting of Shareholders on May 14, 2019 in Boston, Massachusetts. The results of the matters voted on by the shareholders are set forth below.

1.    The election of directors:
 
Votes For
 
Withheld
 
Broker
Non-Votes
 
 
 
 
 
 
Felix Baker
143,053,861
 
52,164,756
 
7,636,326
David R. Brennan
192,892,096
 
2,326,521
 
7,636,326
Christopher J. Coughlin
192,620,486
 
2,598,131
 
7,636,326
Deborah Dunsire
173,529,246
 
21,689,371
 
7,636,326
Paul A. Friedman
130,569,067
 
64,649,550
 
7,636,326
Ludwig N. Hantson
194,949,062
 
269,555
 
7,636,326
John T. Mollen
192,268,289
 
2,950,328
 
7,636,326
Francois Nader
194,989,077
 
229,540
 
7,636,326
Judith A. Reinsdorf
194,772,483
 
446,134
 
7,636,326
Andreas Rummelt
194,080,495
 
1,138,122
 
7,636,326


2.
Ratification of the appointment of PricewaterhouseCoopers LLP as Alexion's independent registered public accounting firm:
Votes For
 
Votes Against
 
Abstentions
201,585,947
 
1,092,769
 
176,227

3.
The non-binding advisory vote to approve the compensation paid to Alexion’s named executive officers as described in Alexion’s 2019 proxy statement:
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
164,139,115
 
30,716,758
 
362,744
 
7,636,326

4.
Shareholder proposal requesting that the Board of Directors amend the proxy access provisions set forth in Alexion's By-laws:

Votes For
 

Votes Against
 

Abstentions
 

Broker Non-Votes
45,870,732
 
149,027,700
 
320,185
 
7,636,326

 




Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 17, 2019
 
ALEXION PHARMACEUTICALS, INC.
 
 
By:    /s/ Doug Barry  
Name: Doug Barry
Title: Vice President, Corporate Law